TAK Stock: Price, Earnings History and SEC Filings
Takeda Pharmaceutical Company Limited (TAK) last traded at $20.91, up 4.50% on the latest session and up 15.0% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $0.51 against an analyst estimate of $0.31, a beat of 64.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TAK earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $0.51 | $0.31 | +64.52% |
| Jun 2026 | Jul 30, 2026 | $0.48 | $0.41 | +17.07% |
| Mar 2026 | May 13, 2026 | $0.28 | $0.21 | +33.33% |
| Dec 2025 | Jan 29, 2026 | $0.48 | $0.55 | -12.73% |
TAK beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for TAK
Insider filing activity
TAK insiders filed 19 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
TAK news
- Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday TradingOct 30, 2026 · finance.yahoo.com
- What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings CallOct 30, 2026 · marketbeat.com
- Takeda (TAK) Q2 2026 Earnings Call TranscriptOct 29, 2026 · fool.com
- Takeda H1 profit rises on cost savings, currency gains; hikes FY outlookOct 29, 2026 · finance.yahoo.com
- Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline MilestonesOct 29, 2026 · finance.yahoo.com
- 2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion ProteinOct 26, 2026 · finance.yahoo.com
- Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer StudyOct 23, 2026 · finance.yahoo.com
- Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center StageOct 22, 2026 · marketbeat.com
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TAK) is a US-listed public company on NYSE. The SEC classifies its business as Pharmaceutical Preparations.